Thank you for the submission. Here is access to the On Demand Webinar: The Need for Woman Controlled Contraceptive Methods for Dual Protection.
view and download the PDF slide-deck below.
- How can we encourage our patients to use dual protection methods
- The physical and emotional long term effects of STIs
- Prevention of Zika virus, and similar infectious diseases
In this fast-paced, half-hour webinar, a women’s healthcare experts will share the details and data related to the FC2 Female Condom and discuss best practices for consultation and prescription for the product. The panel will provide a better understanding of the dual protection benefits of FC2, and respond to audience questions about basic use, clinical aspects and patient access .
|Moderator: Beth Kelsey, EdD, APRN, WHNP-BC, FAANP is a board certified women’s health nurse practitioner. She is currently assistant professor at Ball State University School of Nursing teaching in their master’s in nursing and DNP programs. Dr. Kelsey is the editor-in-chief of Women’s Healthcare: A Clinical Journal for NPs – the official journal of the National Association of Nurse Practitioners in Women’s Health (NPWH). She is also director of publications for NPWH.|
|Presenter: Margaret Semisch McCann, MSN, CRNP, WHNP-BC is a Lecturer in Women’s Health in the Nurse Practitioner Program at the University of Pennsylvania School of Nursing.|
|Presenter: Sheryl A. Ross, M.D., “Dr. Sherry,” is an award-winning OB/GYN, author, entrepreneur and women’s health expert. Over the course of her 25+ years of practice, Dr. Sherry has received the Patient’s Choice Award for Compassionate Doctor Recognition for five years running, the Patient’s Choice Award for Best OB/GYN for six years running, been selected as a 2017 Southern California Super Doctor, a Los Angeles Best Doctor by the Hollywood Reporter, and a Top Doctor in Obstetrics & Gynecology by Castle Connolly.|
|Presenter: Mr. Brian Groch has served as Chief Commercial Officer of the Company since January 2017. Mr. Groch served as Chief Commercial Officer of Telesta Therapeutics Inc., a biotechnology company, from October 2015 until December 2016, overseeing the commercial strategy including, the prelaunch and launch plan for the first immunotherapeutic for bladder cancer in 25 years. From 2014 until 2015, Mr. Groch served as Vice President Market Access for Horizon Therapeutics, Inc., a pharmaceutical company focused on rare diseases. Mr. Groch served as Head of Market Access for Dendreon Corporation, a biotechnology company that developed and launched PROVENGE® for metastatic prostate cancer, from 2010 until 2013. Mr. Groch began his career at Merck & Co., where he rose through the sales and marketing ranks from 1989 to 2002 and was part of the product launches and promotion for ZOCOR®, PRILOSEC®, PLENDIL®, COZAAR®, HYZAAR®, TRUSOPT®, FOSAMAX®, MAXALT® and PROSCAR® (a drug to treat benign prostatic hyperplasia).|